Previsioni

Acquista	2
Mantieni	3
Vendi	0

Notizie Vai al feed delle notizie

Sandoz launches test market for semaglutide generics in Canada and Brazil

Sandoz plans test launches of a generic semaglutide injection in Canada and Brazil later this year to observe market reactions, price levels and patient segments. CEO Richard Saynor emphasizes great uncertainty about the market size after semaglutide patents expire and notes that a possible launch is not yet included in the 2026 forecast. Analyst estimates see rising sales of generic semaglutide in coming years, but the overall impact on Europe and the US remains unclear as exclusive rights still exist there. » Altro su finanzen.net
Sandoz launches Denosumab biosimilars Wyost and Jubbonti in Europe

Sandoz has launched the biosimilar copies Wyost and Jubbonti in Europe. The products target the market for denosumab patients and expand the generics and biosimilars specialist’s portfolio. » Altro su finanzen.net
Sandoz share: one-year gain of 36.1 percent

Had one invested 1,000 CHF in Sandoz a year ago, one would now hold 29.002 shares worth 1,361.37 CHF, corresponding to a price rise of 36.14 percent from the closing price of 34.48 CHF to 46.94 CHF (16 September 2025). The Sandoz share debuted on 4 October 2023 with an initial price of 24.00 CHF. Stock splits and dividends are not included in the calculation. » Altro su finanzen.net

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2024, Sandoz (ADR) ha già distribuito 0,46€ di dividendi. L'ultimo pagamento è avvenuto a giugno 2024.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Sandoz (ADR) ha registrato ricavi pari a 5.06b€ e un utile netto di 95.71m€

(EUR)	giu 2026	YoY
Ricavi	+5.06b	-
Utile lordo	+2.36b	-
Utile netto	+95.71m	-
EBITDA	+982.60m	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+32.60b€
Numero di azioni	432.69m
Massimo/minimo a 52 settimane	+80,80€ - +47,56€
Dividendi	No
Beta	0,49
Rapporto P/E	+58,09
Rapporto PEG	+0,31
Rapporto P/B	+4,23
Rapporto P/S	+3,29

Profilo aziendale

Die Sandoz Group AG entwickelt, produziert und vertreibt weltweit generische Arzneimittel und Biosimilars. Sie entwickelt, produziert und vermarktet fertige Darreichungsformen von Arzneimitteln mit kleinen Molekülen für Dritte. Darüber hinaus bietet das Unternehmen Produkte auf Protein- oder anderer Biotechnologiebasis, einschließlich Biosimilars, sowie biotechnologische Produktionsdienstleistungen und Antiinfektiva, wie pharmazeutische Wirkstoffe und Zwischenprodukte, vor allem Antibiotika, an. Das Unternehmen wurde 1886 gegründet und hat seinen Hauptsitz in Rotkreuz, Schweiz.

Nome	Sandoz (ADR)
CEO	Richard Saynor
Sede centrale	Basel, zg Svizzera
Sito web	sandoz.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	04/10/2023
Dipendenti	23.000